Viruses

New nference Study Reveals Mortality and Racial Disparities in COVID-19 Anticoagulant Treatments

Retrieved on: 
Wednesday, March 10, 2021
Academic journals, Health, Zoonoses, Virology, Viruses, Coronavirus disease

An additional study of the largest ICU dataset, accepted by Journal of Medical Virology, " Healthcare disparities among anticoagulation therapies for severe COVID-19 patients in the multi-site VIRUS registry ", reveals disparities between which medicines were most often prescribed to black and white patients.

Key Points: 
  • An additional study of the largest ICU dataset, accepted by Journal of Medical Virology, " Healthcare disparities among anticoagulation therapies for severe COVID-19 patients in the multi-site VIRUS registry ", reveals disparities between which medicines were most often prescribed to black and white patients.
  • Journal of Medical Virology is a peer-reviewed publication of original scientific papers on fundamental as well as applied research concerning viruses affecting humans.
  • "There is currently no standard of care for COVID-associated coagulopathy," said Venky Soundararajan, PhD, co-founder and chief scientific officer of nference.
  • Through its powerful augmented intelligence software nferX, nference is transforming health care by making biomedical knowledge computable.

AIkido Pharma Provides Update on its Antiviral Platform, Including the Virus That Causes COVID-19

Retrieved on: 
Monday, February 22, 2021
Antiviral drugs, Medical specialties, Medicine, Health sciences, Zoonoses, Sarbecovirus, Bat virome, Broad-spectrum antiviral drug, Viruses, Coronavirus, Severe acute respiratory syndrome coronavirus, Coronavir

These new compounds are currently being tested against Influenza virus with testing on SARS-CoV-2 in the near future.

Key Points: 
  • These new compounds are currently being tested against Influenza virus with testing on SARS-CoV-2 in the near future.
  • Subsequently, the top analogs from eachseries of leadcompounds will be selected for tests of their anti-viral effects in a SARS-CoV-2 mouse model.
  • AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics.
  • The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

20/20 Offering Lab Test for Measuring Antibody Levels Associated with Vaccine Efficacy

Retrieved on: 
Thursday, December 17, 2020
General Health, Infectious diseases, Health, Science, Other Science, Medicine, Medical research, Health sciences, Health care, Moderna, Roche Diagnostics, RNA vaccine, Viruses, COVID-19 testing, 20/20’s Pandemic Response, 20/20 GeneSystems:

The test manufacturer Roche Diagnostics announced last week that their product will be used in ongoing clinical trials of the Moderna vaccine.

Key Points: 
  • The test manufacturer Roche Diagnostics announced last week that their product will be used in ongoing clinical trials of the Moderna vaccine.
  • Measuring the quantitative levels of anti-[spike] SARS-CoV-2 antibodies using Roches test will help Moderna to gain valuable insights into the correlation between protection from vaccination and antibody levels.
  • Quantitative tests permit individuals to monitor changes in their antibody levels over time and may help assess susceptibility to future infections.
  • You may obtain a copy of the offering circular that is part of that offering statement through this link.

Twist Bioscience Expands Infectious Disease Product Line Adding Comprehensive Viral Panel

Retrieved on: 
Monday, November 16, 2020
Software, Biotechnology, Pharmaceutical, Health, Data management, Infectious diseases, Technology, Genetics, Viruses, the Twist Comprehensive Viral Research Panel, Twist Bioscience Corporation

With a renewed focus on public health and the impact of viral identification and containment, we are launching the Twist Comprehensive Viral Research Panel for researchers globally, said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.

Key Points: 
  • With a renewed focus on public health and the impact of viral identification and containment, we are launching the Twist Comprehensive Viral Research Panel for researchers globally, said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • This innovative product contains over one million unique probes to screen for 3,153 viral human and non-human pathogens.
  • The panel covers all viral genome types (ssDNA, dsDNA, ssRNA, and dsRNA) and allows for quick capture and sequencing of unknown pathogens and highly divergent viral strains.
  • The Twist Comprehensive Viral Research Panel includes analysis on the One Codex platform allowing customers to generate easy-to-share publication-ready visuals and viral identification reporting for a complete solution from panel to results.

AIkido Pharma Inc. Announces Publication of Favorable Peer Reviewed Study of Newly Licensed Antiviral Compounds

Retrieved on: 
Friday, November 13, 2020
Antivirals, Sarbecovirus, Medical specialties, Respiratory diseases, Infectious diseases, Broad-spectrum antiviral drug, Viruses, Severe acute respiratory syndrome, Antiviral drug, Coronavirus disease, Science diplomacy and pandemics, Antibody-dependent enhancement

The publication reports studies on newly discovered antiviral compounds that were developed using a computer modeling approach.

Key Points: 
  • The publication reports studies on newly discovered antiviral compounds that were developed using a computer modeling approach.
  • The lead compounds were found to have broad-spectrum antiviral activity, inhibiting influenza virus, Ebola, Marburg, MERS-CoV, SARS-CoV, and SARS-CoV2, the virus that causes COVID-19.
  • Mr. Anthony Hayes, CEO of AIkido stated, "The results of this peer reviewed study provide encouraging data for Company's newly licensed compounds.
  • I am particularly excited with the data that demonstrates inhibition of SARS-CoV2 by the lead compounds.

Prominent Australian and Russian Research Institutions Join Global Virus Network to Combat Viral Diseases

Retrieved on: 
Wednesday, September 9, 2020
Sarbecovirus, Medical specialties, Animal diseases, Microbiology, Zoonoses, Viruses, Bat virome, Severe acute respiratory syndrome coronavirus, Emergent virus, Severe acute respiratory syndrome

The two new institutions bring GVN's total number of Centers of Excellence to 57, along with 10 affiliates in 33 countries.

Key Points: 
  • The two new institutions bring GVN's total number of Centers of Excellence to 57, along with 10 affiliates in 33 countries.
  • "EVIT will strengthen our depth and collaborative network in arbovirology, particularly in the Asia-Pacific region, Southeast Asia, India, South America and South Africa.
  • The Chumakov Center has unique expertise in varying areas of virology with many global connections, making it Russia's leading research organization in the field of virology."
  • Additionally, EVIT focuses on emerging viruses such as Hendra and SARS-CoV-2, and established viruses such as influenza virus and respiratory syncytial virus.

Independent Laboratory Testing Demonstrates APT™ T3X Formulation Neutralizes COVID-19 (SARS-CoV-2 virus)

Retrieved on: 
Wednesday, September 2, 2020
Operating systems, Software, Free software, Virology, Viruses, APT, Apt, Vaucluse, Vaccine

"While the world anxiously awaits a vaccine, APT T3X is the type of protection so many have been hoping for.

Key Points: 
  • "While the world anxiously awaits a vaccine, APT T3X is the type of protection so many have been hoping for.
  • In the meantime, APT T3X provides the type of protection that could be key to our schools and economy reopening fully and safely."
  • The research concludes that APT T3X effectively neutralizes viral infectivity within seconds.
  • That's why we sent APT T3X to an independent virology lab for proper antiviral evaluation and tests.

2020 Western Equine Encephalitis - Pipeline Review, H1 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 30, 2020
Infectious diseases, Pharmaceutical, Health, Medical specialties, Viral encephalitis, Medicine, Clinical medicine, Viruses, Neglected tropical diseases, Tropical diseases, RTT, Equine encephalitis, Western equine encephalitis virus, Arbovirus, Encephalitis

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Western Equine Encephalitis - Pipeline Review, H1 2020, provides an overview of the Western Equine Encephalitis (Infectious Disease) pipeline landscape.

Key Points: 
  • The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Western Equine Encephalitis - Pipeline Review, H1 2020, provides an overview of the Western Equine Encephalitis (Infectious Disease) pipeline landscape.
  • Western equine encephalitis is caused by the western equine encephalitis virus, an arbovirus.
  • The publisher's Pharmaceutical and Healthcare latest pipeline guide Western Equine Encephalitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Western Equine Encephalitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Western Equine Encephalitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Western Equine Encephalitis and features dormant and discontinued projects.

Cidara Therapeutics Announces Formation of Scientific Advisory Board

Retrieved on: 
Monday, July 27, 2020
Virology, Viruses

SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced the formation of a scientific advisory board (SAB) and the appointment of four leading experts in viral and fungal infections and hematology.

Key Points: 
  • SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced the formation of a scientific advisory board (SAB) and the appointment of four leading experts in viral and fungal infections and hematology.
  • The SAB will work closely with the Cidara management team to help guide the direction and design of the companys development programs with an emphasis on the continued development and expansion of the companys Cloudbreak Antiviral Conjugate (AVC) program.
  • We are proud to have globally recognized key opinion leaders in virology, fungal diseases, transplant and hematology joining our newly formed SAB, said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.
  • Cidara is headquartered in San Diego, California.

In Midst of Government Charges, 4000 Shincheonji Church Members Agree to Donate Plasma for Coronavirus

Retrieved on: 
Friday, July 17, 2020
Viruses, Articles, Coronaviridae, Animal virology, Coronavirus, Pandemic, Daegu

Thepersecuted.orgattempts to answer this question in its latest analysis, Church and State: The Changing Landscape of Religion in South Korea .

Key Points: 
  • Thepersecuted.orgattempts to answer this question in its latest analysis, Church and State: The Changing Landscape of Religion in South Korea .
  • Recently during the Coronavirus pandemic, a super-spreader event in February at Shincheonji Church's Daegu branch resulted in the infection of over 4,000 members as well as several deaths.
  • Just this month, the vast majority of those individuals agreed to collaborate with the hospitals and government to donate their blood plasma for the Coronavirus relief effort.
  • In the midst of this, the Korean government pressed charges against Shincheonji church.